Delia D'Avola, Valentín Cuervas‐Mons, Josep Martí, Jorge Ortiz de Urbina, Laura Lladó, Carlos Jimenez, Esteban Otero, Francisco Suarez, Juan M. Rodrigo, Miguel‐Angel Gómez, Enrique Fraga, Pedro Lopez, M. Trinidad Serrano, Antonio Rios, Emilio Fábrega, José Ignacio Herrero – 3 February 2017 – Cardiovascular (CV) diseases are recognized longterm causes of death after liver transplantation (LT). The objective of this multicenter study was to analyze the prevalence and the evolution of CV risk factors and CV morbidity and mortality in 1819 LT recipients along 5 years after LT.

R. Todd Stravitz – 3 February 2017

Kent Benner, Ken Flora, Pippa Newell – 3 February 2017

Suraj D. Serai, Andrew T. Trout, Claude B. Sirlin – 3 February 2017

Timucin Taner – 3 February 2017

Suraj D. Serai, Andrew T. Trout, Claude B. Sirlin – 3 February 2017

Yaron Rotman, Brent A. Neuschwander‐Tetri – 2 February 2017

Ashwin Rammohan, Sanjay Govil, Joy Vargese, Venugopal Kota, Mettu S. Reddy, Mohamed Rela – 2 February 2017 – Biliary complications (BCs) remain a significant cause of morbidity following liver transplantation (LT). This series of 640 LT recipients with a blend of living and deceased donor transplants was analyzed to determine the incidence, risk factors, management protocol, and outcomes in these patients. Review of a prospectively collected database of transplant recipients operated between August 2009 and June 2016 was performed.

Catarina Oliveira, Carole Fournier, Véronique Descamps, Virginie Morel, Corey A. Scipione, Rocco Romagnuolo, Marlys L. Koschinsky, Agnès Boullier, Paulo Marcelo, Jean‐Marc Domon, Etienne Brochot, Gilles Duverlie, Catherine Francois, Sandrine Castelain, Francois Helle – 2 February 2017 – The development of different cell culture models has greatly contributed to increased understanding of the hepatitis C virus (HCV) life cycle. However, it is still challenging to grow HCV clinical isolates in cell culture.

Joon‐Young Ohm, Gi‐Young Ko, Kyu‐Bo Sung, Dong‐Il Gwon, Heung Kyu Ko – 2 February 2017 – The purpose of this article is to evaluate and compare the safety and efficacy of endovascular management of the portal vein (PV) via percutaneous transsplenic access versus percutaneous transhepatic access in liver transplantation (LT) recipients. A total of 18 patients who underwent endovascular management of PV via percutaneous transhepatic (n = 8) and transsplenic (n = 10) access were enrolled.